Benchmark Maintains Buy on HNI, Lowers Price Target to $65

Benzinga Newsdesk www.benzinga.com Negative 63.9%

Neg 63.9% Neu 0% Pos 0%

Benchmark analyst Reuben Garner maintains HNI (NYSE:HNI) with a Buy and lowers the price target from $75 to $65.

Comments

No comments yet. Be the first!